Welcome to INSUPPORT®
Justice System Administrators
INSUPPORT® was created by INDIVIOR to provide information for patients transitioning from incarceration to an outpatient community-based setting.
Please see the full Prescribing Information including BOXED WARNING for Sublocade (buprenorphine) injection for subcutaneous use (CIII), Important Safety Information for Sublocade and Medication Guide for SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII.
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.
Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.